Law360, New York (October 02, 2006, 12:00 AM ET) -- The U.S. Supreme Court heard oral arguments Wednesday in the patent-license dispute between biotechnology rivals MedImmune Inc. and Genentech Inc., in a case that will determine just how stable relationships between patent holders and licensees can be.
The high court agreed to hear the case in March, putting the spotlight on a patent dispute over Synagis, a drug designed to prevent dangerous respiratory tract infections that afflict about 125,000 children in the United States each year.
One of 38 cases accepted by the high court for...
Supreme Court Hears Landmark MedImmune Appeal
To view the full article, take a free trial now.
